New combo therapy aims to tame rheumatoid arthritis
NCT ID NCT06590090
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tests whether adding a new drug, natrunix, to the standard treatment methotrexate helps control moderate to severe rheumatoid arthritis better than methotrexate alone. About 108 adults who have not responded well enough to methotrexate will receive weekly injections for 14 weeks, followed by an open-label extension where everyone gets natrunix. The main goal is to see if more people achieve at least a 20% improvement in arthritis symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.